Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AbbVie 3D regimen and endothelial function in chronic hepatitis C
ACTRN12615001167550Phase 4Completed
- Sponsor
- John Hunter Hospital
- Start
- Aug 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin in hepatitis C virus infection (2 arms), sponsored by John Hunter Hospital. Primary endpoint: Change in RH-PAT index over 12 weeks of HCV treatment compared with a 4 week baseline period. Started Aug 2015; status: completed.
02
Drugs
paritaprevirritonavirombitasvirdasabuvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ACTRN12615001167550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615001167550.